Key result
Adjuvant trastuzumab therapy for HER2-positive breast cancer improves prognosis but is associated with a risk for cardiotoxicity, requiring appropriate patient monitoring.
Why the study?
What are the prevalence, patient characteristics, and risk factors for cardiotoxicity associated with adjuvant trastuzumab therapy in women with HER2-positive breast cancer?
What are the prevalence, patient characteristics, and risk factors for cardiotoxicity associated with adjuvant trastuzumab therapy in women with HER2-positive breast cancer?
Understanding risk factors and appropriate monitoring for trastuzumab-induced cardiotoxicity allows for safe and effective use of this adjuvant therapy in HER2-positive breast cancer.
Answers are grounded in this paper and cite their sources.
Requires vigilant monitoring in trastuzumab recipients; leaves open refined risk stratification for prospective validation.
Before the advent of the human epidermal growth factor receptor 2 (HER2)-targeted monoclonal antibody trastuzumab, HER2-positive breast cancers were difficult to treat and had a poor prognosis. Adjuvant trastuzumab is now an important part of the treatment regimen for many women with HER2-positive breast cancer and has undoubtedly resulted in a significant improvement in prognosis, but it is associated with a risk for cardiotoxicity. In this review, we describe the prevalence, patient characteristics, and risk factors for cardiotoxicity associated with use of adjuvant trastuzumab. Understanding risk factors for trastuzumab-induced cardiotoxicity and appropriate patient monitoring during trastuzumab treatment allows for safe and effective use of this important adjuvant therapy.
No takes yet. Share an insight, caveat, or question.
Onitilo et al. (2014) conducted a review in HER2-positive breast cancer. Adjuvant trastuzumab was evaluated on Cardiotoxicity. Adjuvant trastuzumab therapy for HER2-positive breast cancer improves prognosis but is associated with a risk for cardiotoxicity, requiring appropriate patient monitoring.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: